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decade enabling the delivery of high radiation doses, 
reducing side-effects in tumour-adjacent normal tissues. 
While increasing local tumour control, current and future 
efforts ought to deal with microscopic disease at a distance 
of the primary tumour, ultimately responsible for disease-
progression. This talk will explores the possibility of bimodal 
treatment combining radiotherapy with immunotherapy. L19 
targets the extra domain B (ED-B) of fibronectin, a marker 
for tumor neoangiogenesis, and can be used as 
immunocytokine when coupled to IL2. We hypothesize that 
radiotherapy in combination with L19-IL2 provides an 
enhanced antitumor effect, which is dependent on ED-B 
expression.  
EXPERIMENTAL DESIGN: Mice were injected with syngeneic 
C51 colon carcinoma, Lewis lung carcinoma (LLC), or 4T1 
mammary carcinoma cells. Tumor growth delay, underlying 
immunologic parameters, and treatment toxicity were 
evaluated after single-dose local tumor irradiation and 
systemic administration of L19-IL2 or equimolar controls.  
RESULTS: ED-B expression was high, intermediate, and low 
for C51, LLC, and 4T1, respectively. The combination therapy 
showed (i) a long-lasting synergistic effect for the C51 model 
with 75% of tumors being cured, (ii) an additive effect for the 
LLC model, and (iii) no effect for the 4T1 model. The 
combination treatment resulted in a significantly increased 
cytotoxic (CD8(+)) T-cell population for both C51 and LLC. 
Depletion of CD8(+) T cells abolished the benefit of the 
combination therapy.  
CONCLUSIONS: These data provide the first evidence for an 
increased therapeutic potential by combining radiotherapy 
with L19-IL2 in ED-B-positive tumors. This new opportunity in 
cancer treatment will be investigated in a phase I clinical 
study for patients with an oligometastatic solid tumor 
(NCT02086721). An animation summarizing our results is 
available at 
https://www.youtube.com/watch?v=xHbwQuCTkRc .  
REFERENCE:. Zegers CM1, Rekers NH2, Quaden DH3, Lieuwes 
NG2, Yaromina A2, Germeraad WT4, Wieten L5, Biessen EA6, 
Boon L7, Neri D8, Troost EG2, Dubois LJ2, Lambin P2. 
Radiotherapy combined with the immunocytokine L19-IL2 
provides long-lasting antitumor effects. Clin Cancer Res. 2015 
Mar 1;21(5):1151-60. 
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For a number of tumour types there is increasing acceptance 
that cancer stem cells play an important role in tumour 
initiation and recurrence after treatment. In line with this 
model, increasing evidence indicates that cancer stem cells 
exhibit resistance to conventional cytotoxic agents. In the 
case of glioblastoma, an incurable primary brain tumour 
associated with dismal prognosis and devastating effects on 
quality of life, a series of influential publications have 
demonstrated that the radiation resistance of glioblastoma 
stem-like cells (GSC) is associated with constitutive 
upregulation of the DNA damage response (DDR).  
In this presentation I will outline the evidence supporting this 
model, and present new data that elucidates the relative 
contributions of DNA repair and cell cycle checkpoints to this 
phenotype. Subsequently I will investigate the effects of 
inhibiting various components of the DDR, alone and in 
combination, and discuss the potential clinical application of 
a number of promising new small molecule inhibitors. 
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Recent technological advances in DNA sequencing with 
greater speed and resolution at lower costs has provided new 
insights in cancer genetics. The next-generation sequencing 
(NGS) technology is tremendously facilitating the in-depth 
genome-wide search for genetic alterations which might 
significantly contribute to aggressive and/or treatment-
resistant phenotypes of cancers, thereby establishing the 
basis for improvement of cancer treatment. We hypothesized 
that NGS should also be useful for dissecting the molecular 
mechanisms of radioresistance in squamous cell carcinoma of 
the head and neck (HNSCC). 
We therefore applied the technology of targeted NGS to 
clinical samples from two multicenter studies of definitive 
and adjuvant cisplatin-based chemoradiation of locally 
advanced HNSCC. We evaluated whether by molecular 
profiling using targeted NGS it is possible to prospectively 
discriminate between patients who clearly benefit from 
chemoradiation and those with poor locoregional control and 
reduced overall survival after such treatment. Our studies 
could confirm previous reports of poor efficacy of 
radiotherapy in HNSCC tumors harboring TP53 mutations. For 
the first time, we identified additional mutations in other 
genes as predictive biomarkers of outcome after 
chemoradiation. 
The talk will summarize the results of NGS studies in HNSCC 
and other carcinoma models, thereby focusing on studies in 
which molecular mechanisms involved in radio-
/chemoresistance have been addressed. It will present 
unpublished results from functional studies in preclinical 
models in which we are evaluating the mode of interaction of 
distinct genetic variants with radio-/chemoresistance. 
Concepts of how to integrate the results from NGS into novel 
personalized treatment strategies for HNSCC will be 
discussed. 
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Massive parallel sequencing technologies (also: next 
generation sequencing) have revolutionized our 
understanding of the genomic and transcriptional makeup of 
malignomas. Aided by equally impressive developments in 
sequencing- and chip-based epigenetic tumor profiling and 
developments in mass spectrometry which allow for a 
comprehensive proteomic and metabolomic profiling we are 
now able to draw fairly comprehensive multi –omics 
landscapes of individual tumors both from tissue but 
increasingly also from blood or circulating tumor cells. 
However, many issues remain still challenging when it comes 
to a translation of these findings into a potential clinical 
outreach. This includes matters of tumor heterogeneity 
specifically with respect to tumor evolution in the metastatic 
setting as well as under therapeutic pressure. Other widely 
unresolved issues include the usefulness of identified drivers 
as novel targets for therapy or as predictive biomarkers and 
strategies to implement broad high throughput genomic 
testing into individualized patient care. Specifically the 
latter issue will decide which of these multi–omics 
technologies will take the step from tools merely for 
biological research profiling to advanced and modern routine 
clinical care. 
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Gene expression profiles hold great promises for PRO 
(Personalized Radiation Oncology), yet very few - if any - are 
implemented in routine clinical practice and used as 
predictive biomarkers for treatment decisions in radiation 
oncology. 
